Lipid Lowering Therapy and Circulating PCSK9 Concentration
Open accessThe DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Abstract
Hypercholesterolemia, particularly an increase in low-density lipoprotein cholesterol (LDL-C) levels, contributes substantially to the development of coronary artery disease and the risk for cardiovascular events. As the first-line pharmacotherapy, statins have been shown to reduce both LDL-C levels and cardiovascular events. However, despite intensive statin therapy, a sizable proportion of statin-treated patients are unable to achieve the recommended target LDL-C levels, and not all patients can avoid future cardiovascular events. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in cholesterol homeostasis by enhancing the degradation of hepatic low-density lipoprotein receptor (LDLR). Owing to its importance in lipid metabolism, PCSK9 has emerged as a novel pharmacological target for lowering LDL-C levels. In this review, the potential role of circulating PCSK9 as a new biomarker of lipid metabolism is described. Next, previous studies evaluating the effects of lipid-modifying pharmacological agents, particularly statins, on circulating PCSK9 concentrations are summarized. Statins decrease hepatic intracellular cholesterol, resulting in increased LDLRs as well as increased PCSK9 protein. There is a clear dose-response effect of statin treatment on PCSK9 level, as increasing doses of statins also increase the level of circulating PCSK9. Finally, the available therapeutic strategies to inhibit PCSK9 are present. Monoclonal antibodies against PCSK9, in combination with statins, are one of the most promising and novel approaches to achieve further reduction of LDL-C levels and reduce the risk of cardiovascular events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, this has not been confirmed in RCTs [266,479-481], or in meta-analyses of observational and randomized trials [482,483].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [266]
Experimental — accuracy not yet measuredIn the citing paper
“In both the SEAS and SHARP trials, a reduction in CV events was demonstrated in the simvastatin-ezetimibe arm vs. placebo [266,267].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [266]
In the citing paper
“Three modestly sized trials [479-481] and one large randomized trial (SEAS, which included 1873 patients treated with simvastatin 40 mg plus ezetimibe 10 mg or placebo) [266] failed to show a reduction in the clinical progression of aortic stenosis in patients with mild-to-moderate native valve aortic stenosis.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [266]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
Nicholls, S. J., Puri, R., Anderson, T., Ballantyne, C. M., Cho, L., Kastelein, J. J. P., Koenig, W., Somaratne, R., Kassahun, H., Yang, J., et al. (2016) · JAMA · doi:10.1001/jama.2016.16951 · Cited by 1,178
Drug Treatment of Lipid Disorders
Knopp, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410707 · Cited by 845
Zhang, D.-W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702027200 · Cited by 788
Raal, F. J., Stein, E. A., Dufour, R., Turner, T., Civeira, F., Burgess, L., Langslet, G., Scott, R., Olsson, A. G., Sullivan, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61399-4 · Cited by 756
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316222 · Cited by 720
Frank-Kamenetsky, M., Grefhorst, A., Anderson, N. N., Racie, T. S., Bramlage, B., Akinc, A., Butler, D., Charisse, K., Dorkin, R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 642
Seidah (2014) · doi:10.1161/circresaha.114.301621 · Cited by 596
Stein, E. A., Gipe, D., Bergeron, J., Gaudet, D., Weiss, R., Dufour, R., Wu, R., & Pordy, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60771-5 · Cited by 588
Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., Hutabarat, R. M., Clausen, V. A., Karsten, V., Cehelsky, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61914-5 · Cited by 577
Dubuc, G., Chamberland, A., Wassef, H., Davignon, J., Seidah, N. G., Bernier, L., & Prat, A. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000134621.14315.43 · Cited by 570
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
Stroes, E., Colquhoun, D., Sullivan, D., Civeira, F., Rosenson, R. S., Watts, G. F., Bruckert, E., Cho, L., Dent, R., Knusel, B., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.019 · Cited by 526
McKenney, J. M., Koren, M. J., Kereiakes, D. J., Hanotin, C., Ferrand, A.-C., & Stein, E. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.007 · Cited by 514
Robinson, J. G., Nedergaard, B. S., Rogers, W. J., Fialkow, J., Neutel, J. M., Ramstad, D., Somaratne, R., Legg, J. C., Nelson, P., Scott, R., et al. (2014) · JAMA · doi:10.1001/jama.2014.4030 · Cited by 496
Genetic and metabolic determinants of plasma PCSK9 levels
Lakoski, S. G., Lagace, T. A., Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0141 · Cited by 475
Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Roth, E. M., McKenney, J. M., Hanotin, C., Asset, G., & Stein, E. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201832 · Cited by 469
Lambert (2012) · doi:10.1194/jlr.r026658 · Cited by 448
Giugliano, R. P., Desai, N. R., Kohli, P., Rogers, W. J., Somaratne, R., Huang, F., Liu, T., Mohanavelu, S., Hoffman, E. B., McDonald, S. T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61770-x · Cited by 428
Anti-PCSK9 Monotherapy for Hypercholesterolemia
Koren, M. J., Lundqvist, P., Bolognese, M., Neutel, J. M., Monsalvo, M. L., Yang, J., Kim, J. B., Scott, R., Wasserman, S. M., & Bays, H. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.018 · Cited by 411
Navarese, E. P., Kołodziejczak, M., Schulze, V., Gurbel, P. A., Tantry, U., Lin, Y., Brockmeyer, M., Kandzari, D. E., Kubica, J. M., D'Agostino, R. B., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2957 · Cited by 404
Chan, J. C. Y., Piper, D. E., Cao, Q., Liu, D., King, C., Wang, W., Tang, J., Liu, Q., Higbee, J., Xia, Z., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903849106 · Cited by 371
Lipid-reduction variability and antidrug-antibody formation with bococizumab
Ridker, P. M., Tardif, J.-C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W., Kastelein, J. J. P., Kim, A. M., Koenig, W., Nissen, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614062 · Cited by 369
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Langslet, G., Bays, H., Blom, D., Eriksson, M., Dent, R., Wasserman, S. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.006 · Cited by 361
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., & Wiviott, S. D. (2015) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2015.08.004 · Cited by 360
Jeong, H. J., Lee, H.-S., Kim, K.-S., Kim, Y.-K., Yoon, D., & Park, S. W. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700443-jlr200 · Cited by 331
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
Careskey, H. E., Davis, R. A., Alborn, W. E., Troutt, J. S., Cao, G., & Konrad, R. J. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700437-jlr200 · Cited by 313
Graham, M. J., Lemonidis, K. M., Whipple, C. P., Subramaniam, A., Monia, B. P., Crooke, S. T., & Crooke, R. M. (2007) · Journal of Lipid Research · doi:10.1194/jlr.c600025-jlr200 · Cited by 293
Dong, B., Wu, M., Li, H., Kraemer, F. B., Adeli, K., Seidah, N. G., Park, S. W., & Liu, J. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m003566 · Cited by 266
Berge, K. E., Ose, L., & Leren, T. P. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000204337.81286.1c · Cited by 236
Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels
Dias, C. S., Shaywitz, A. J., Wasserman, S. M., Smith, B. P., Gao, B., Stolman, D. S., Crispino, C. P., Smirnakis, K. V., Emery, M. G., Colbert, A., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.986 · Cited by 235
Welder, G., Zineh, I., Pacanowski, M. A., Troutt, J. S., Cao, G., & Konrad, R. J. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m008144 · Cited by 227
A new method for measurement of total plasma PCSK9: clinical applications
Dubuc, G., Tremblay, M., Paré, G., Jacques, H., Hamelin, J., Benjannet, S., Boulet, L., Genest, J., Bernier, L., Seidah, N. G., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m900273-jlr200 · Cited by 222
Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
Mayne, J., Dewpura, T., Raymond, A., Cousins, M., Chaplin, A., Lahey, K. A., LaHaye, S. A., Mbikay, M., Ooi, T., & Chrétien, M. (2008) · Lipids in Health and Disease · doi:10.1186/1476-511x-7-22 · Cited by 217
Molecular basis of PCSK9 function
Lambert, G., Charlton, F., Rye, K.-A., & Piper, D. E. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.06.010 · Cited by 197
PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study
Cheng, J. M., Oemrawsingh, R. M., Garcia-Garcia, H. M., Boersma, E., van Geuns, R.-J., Serruys, P. W., Kardys, I., & Akkerhuis, K. M. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.03.010 · Cited by 184
Kosenko, T., Golder, M., Leblond, G., Weng, W., & Lagace, T. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.421370 · Cited by 181
Gupta, N., Fisker, N., Asselin, M.-C., Lindholm, M., Rosenbohm, C., Ørum, H., Elmén, J., Seidah, N. G., & Straarup, E. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010682 · Cited by 174
Functional characterization of Narc 1, a novel proteinase related to proteinase K
Naureckiene, S., Ma, L., Sreekumar, K. R., Purandare, U., Lo, C. F., Huang, Y., Chiang, L. W., Grenier, J. M., Ozenberger, B. A., Jacobsen, J. S., et al. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.09.011 · Cited by 173
Lambert, G., Ancellin, N., Charlton, F., Comas, D., Pilot, J., Keech, A., Patel, S., Sullivan, D. R., Cohn, J. S., Rye, K.-A., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.099747 · Cited by 166
Persson, L., Cao, G., Ståhle, L., Sjöberg, B. G., Troutt, J. S., Konrad, R. J., Gälman, C., Wallén, H., Eriksson, M., Hafström, I., et al. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.214130 · Cited by 165
Chen, S. N., Ballantyne, C. M., Gotto, A. M., Tan, Y., Willerson, J. T., & Marian, A. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.051 · Cited by 162
Awan, Z., Seidah, N. G., MacFadyen, J. G., Benjannet, S., Chasman, D. I., Ridker, P. M., & Genest, J. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.172932 · Cited by 149
Sanderson, L. M., Boekschoten, M. V., Desvergne, B., Müller, M., & Kersten, S. (2010) · Physiological Genomics · doi:10.1152/physiolgenomics.00127.2009 · Cited by 145
Cariou, B., Ouguerram, K., Zaïr, Y., Guerois, R., Langhi, C., Kourimate, S., Benoit, I., Le May, C., Gayet, C., Belabbas, K., et al. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.194191 · Cited by 140
Ni, Y. G., Di Marco, S., Condra, J. H., Peterson, L. B., Wang, W., Wang, F., Pandit, S., Hammond, H. A., Rosa, R., Cummings, R. T., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m011445 · Cited by 134
Raal, F., Panz, V., Immelman, A., & Pilcher, G. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.112.000028 · Cited by 132
Lipoprotein(a) in Homozygous Familial Hypercholesterolemia
Kraft, H. G., Lingenhel, A., Raal, F. J., Hohenegger, M., & Utermann, G. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.2.522 · Cited by 121
Extracellular loop C of NPC1L1 is important for binding to ezetimibe
Weinglass, A. B., Kohler, M., Schulte, U., Liu, J., Nketiah, E. O., Thomas, A., Schmalhofer, W., Williams, B., Bildl, W., McMasters, D. R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800936105 · Cited by 113
Half a Century Tales of Familial Hypercholesterolemia (FH) in Japan
Mabuchi, H. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv16008 · Cited by 111
Browning, J. D., & Horton, J. D. (2010) · Journal of Lipid Research · doi:10.1194/jlr.p009860 · Cited by 105
Zhang, L., McCabe, T., Condra, J. H., Ni, Y. G., Peterson, L. B., Wang, W., Strack, A. M., Wang, F., Pandit, S., Hammond, H., et al. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.3524 · Cited by 101
Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men
Tremblay, A. J., Lamarche, B., Lemelin, V., Hoos, L., Benjannet, S., Seidah, N. G., Davis, J. H. R., & Couture, P. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m011080 · Cited by 101
Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9
Kourimate, S., Le May, C., Langhi, C., Jarnoux, A. L., Ouguerram, K., Zaïr, Y., Nguyen, P., Krempf, M., Cariou, B., & Costet, P. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705831200 · Cited by 95
Costet, P., Hoffmann, M. M., Cariou, B., Guyomarch, B., Konrad, T., & Winkler, K. E. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.027 · Cited by 94
Sahebkar, A., Simental‐Mendía, L. E., Guerrero‐Romero, F., Golledge, J., & Watts, G. F. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12536 · Cited by 93
Zhu, Y. M., Anderson, T. J., Sikdar, K., Fung, M., McQueen, M. J., Lonn, E. M., & Verma, S. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306172 · Cited by 83
PCSK9 and Atherosclerosis - Lipids and Beyond
Shapiro, M. D., & Fazio, S. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17003 · Cited by 83
Plasma PCSK9 levels correlate with cholesterol in men but not in women.
Mayne, J., Raymond, A., Chaplin, A., Cousins, M., Kaefer, N., Gyamera-Acheampong, C., Seidah, N. G., Mbikay, M., Chrétien, M., & Ooi, T. C. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.07.029 · Cited by 81
Tada, H., Kawashiri, M.-A., Yoshida, T., Teramoto, R., Nohara, A., Konno, T., Inazu, A., Mabuchi, H., Yamagishi, M., & Hayashi, K. (2016) · Circulation Journal · doi:10.1253/circj.cj-15-0999 · Cited by 79
Indices of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and Simvastatin
Lakoski, S. G., Xu, F., Vega, G. L., Grundy, S. M., Chandalia, M., Lam, C., Lowe, R. S., Stepanavage, M. E., Musliner, T. A., Cohen, J. C., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1952 · Cited by 74
Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels.
Davignon, J., & Dubuc, G. (2009) · PubMed Central · Cited by 72
Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels
Troutt, J. S., Alborn, W. E., Cao, G., & Konrad, R. J. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m000620 · Cited by 71
Konrad, R. J., Troutt, J. S., & Cao, G. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-38 · Cited by 71
Yamamoto, T., Harada-Shiba, M., Nakatani, M., Wada, S., Yasuhara, H., Narukawa, K., Sasaki, K., Shibata, M.-A., Torigoe, H., Yamaoka, T., et al. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.16 · Cited by 69
Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
Huijgen, R., Fouchier, S. W., Denoun, M., Hutten, B. A., Vissers, M. N., Lambert, G., & Kastelein, J. J. P. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p023994 · Cited by 67
Puri, R., Nissen, S. E., Somaratne, R. M., Cho, L., Kastelein, J. J. P., Ballantyne, C. M., Köenig, W., Anderson, T. J., Yang, J., Kassahun, H., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.01.019 · Cited by 66
Common and Low-Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels
Chernogubova, E., Strawbridge, R., Mahdessian, H., Mälarstig, A., Krapivner, S., Gigante, B., Hellénius, M.-L., de Faire, U., Franco-Cereceda, A., Syvänen, A.-C., et al. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.240549 · Cited by 64
Chan, D. C., Lambert, G., Barrett, P. H. R., Rye, K.-A., Ooi, E. M. M., & Watts, G. F. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.128645 · Cited by 62
Khera, A. V., Qamar, A., Reilly, M. P., Dunbar, R. L., & Rader, D. J. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.10.018 · Cited by 60
Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients
Cariou, B., Bras, M. L., Langhi, C., May, C. L., Guyomarch, B., Krempf, M., & Costet, P. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.04.015 · Cited by 59
Berthold, H. K., Seidah, N. G., Benjannet, S., & Gouni-Berthold, I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060095 · Cited by 59
Hori, M., Ishihara, M., Yuasa, Y., Makino, H., Yanagi, K., Tamanaha, T., Kishimoto, I., Kujiraoka, T., Hattori, H., & Harada-Shiba, M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3066 · Cited by 58
Li, S., Zhu, C.-G., Guo, Y.-L., Xu, R.-X., Zhang, Y., Sun, J., & Li, J.-J. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.25841 · Cited by 57
Lipoprotein a: where are we now?
Tziomalos, K., Athyros, V. G., Wierzbicki, A. S., & Mikhailidis, D. P. (2009) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32832ac21a · Cited by 57
Short-Term Impact of Low-Dose Atorvastatin on Serum Proprotein Convertase Subtilisin/Kexin Type 9
Guo, Y., Liu, J., Xu, R., Zhu, C., Wu, N., Jiang, L., & Li, J. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0129-2 · Cited by 54
Koren, M. J., Kereiakes, D., Pourfarzib, R., Winegar, D., Banerjee, P., Hamon, S., Hanotin, C., & McKenney, J. M. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002224 · Cited by 52
Noguchi, T., Kobayashi, J., Yagi, K., Nohara, A., Yamaaki, N., Sugihara, M., Ito, N., Oka, R., Kawashiri, M., Tada, H., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.02.012 · Cited by 49
Lamon-Fava, S., Diffenderfer, M. R., & Marcovina, S. M. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000070 · Cited by 48
Han, L., Li, M., Liu, Y., Han, C., & Ye, P. (2012) · Pharmacology · doi:10.1159/000335783 · Cited by 43
Nozue, T., Michishita, I., & Mizuguchi, I. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.1651 · Cited by 42
Self-citationPCSK9: A key factor modulating atherosclerosis
Li, S., & Li, J.-J. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.27615 · Cited by 41
Cameron, J., Bogsrud, M. P., Tveten, K., Strøm, T. B., Holven, K. B., Berge, K. E., & Leren, T. P. (2012) · Translational research · doi:10.1016/j.trsl.2012.01.010 · Cited by 37
Nozue, T., Hattori, H., Ogawa, K., Kujiraoka, T., Iwasaki, T., & Michishita, I. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.33407 · Cited by 37
Self-citationChan, D. C., Hamilton, S. J., Rye, K. A., Chew, G. T., Jenkins, A. J., Lambert, G., & Watts, G. F. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01229.x · Cited by 36
Guo, Y., Xu, R., Zhu, C., Wu, N., Cui, Z., & Li, J. (2014) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2014/926087 · Cited by 31
Nozue, T., Yamamoto, S., Tohyama, S., Fukui, K., Umezawa, S., Onishi, Y., Kunishima, T., Sato, A., Nozato, T., Miyake, S., et al. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.12.016 · Cited by 30
Self-citationNozue, T., Hattori, H., Ogawa, K., Kujiraoka, T., Iwasaki, T., Hirano, T., & Michishita, I. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0339-8 · Cited by 29
Self-citationOkada, K., Iwahashi, N., Endo, T., Himeno, H., Fukui, K., Kobayashi, S., Shimizu, M., Iwasawa, Y., Morita, Y., Wada, A., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.07.036 · Cited by 27
Miyoshi, T., Nakamura, K., Doi, M., & Ito, H. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0119-2 · Cited by 20
Hentze, H., Jensen, K. K., Chia, S. M., Johns, D. G., Shaw, R. J., Davis, H. R., Shih, S., & Wong, K. K. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.08.028 · Cited by 15
Xiao, Y., Peng, C., Huang, W. H., Zhang, J., Gao, Y., Kim, J. H., Yeoh, E., & Su, X. (2017) · Circulation Journal · doi:10.1253/circj.cj-16-1142 · Cited by 15
Escape phenomenon of low-density lipoprotein cholesterol during lovastatin treatment
Rubinstein, A., & Weintraub, M. S. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80057-5 · Cited by 13
PCSK9 inhibitors for treating familial hypercholesterolaemia
Mabuchi, H., & Nohara, A. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.205 · Cited by 12
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Chawla, S., Tessarolo Silva, F., Amaral Medeiros, S., Mekary, R., & Radenkovic, D. (2020) · Nutrients · doi:10.3390/nu12123774 · Cited by 185
Johns, D. G., Campeau, L.-C., Banka, P., Bautmans, A., Bueters, T., Bianchi, E., Branca, D., Bulger, P. G., Crevecoeur, I., Ding, F.-X., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063372 · Cited by 167
Metadata
- Authors
- Nozue, T.
- Affiliations
- Yokohama Sakae Kyosai Hospital (JP)
- Corresponding author
- Nozue, Tsuyoshi
- Venue
- Journal of Atherosclerosis and Thrombosis
- Publisher
- Japan Atherosclerosis Society
- Published
- 2017
- Volume
- 24
- Issue
- 9
- Pages
- 895-907
- ISSN
- 1340-3478 (ISSN-L)
- 1880-3873
- PMC
- PMC5587514
- OpenAlex
- W2743198652
- Cited by
- 127
- References
- 100
- Citations by year
- 2026: 4 · 2025: 19 · 2024: 13 · 2023: 11 · 2022: 18 · 2021: 17 · 2020: 20 · 2019: 14 · 2018: 11
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Journal of Atherosclerosis and Thrombosis (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- PCSK9, statins, LDL cholesterol lowering, hypercholesterolemia, LDL receptor degradation, cholesterol homeostasis, PCSK9 inhibitors, PCSK9 monoclonal antibodies, lipid metabolism biomarkers, cardiovascular risk
- MeSH terms
- Ezetimibe, Proprotein Convertase 9, PCSK9 Inhibitors, Antibodies, Monoclonal, Hypolipidemic Agents, Humans, Hypercholesterolemia, Cholesterol, LDL, Niacin, Biomarkers, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Gene Silencing, Lipid Metabolism, Fibric Acids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.